New hope for blood cancer patients: phase 3 trial launches for DZD8586

NCT ID NCT07139873

Recruiting now Disease control Sponsor: Dizal (Jiangsu) Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 33 times

Summary

This study tests a new drug, DZD8586, against standard treatments in 250 adults with chronic lymphocytic leukemia or small lymphocytic lymphoma that has come back or stopped responding to prior therapy. The main goal is to see if DZD8586 can delay cancer growth longer than the doctor's choice of treatment. Participants will be randomly assigned to receive either DZD8586 or another approved therapy.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital
RECRUITING

Nanjing, Jiangsu, China
National Clinical Research Center for Blood Diseases, Blood Disease Hospital & Institute of Hematology, Chinese Academy of Medical Sciences & Peking Union Medical College
RECRUITING

Tianjin, Tianjin Municipality, China

Conditions

Explore the condition pages connected to this study.

CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA